The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

GI Innovation doses first patient in global GI-102 prostate cancer trial

Nov 5, 2026 02:19 (5h ago)

Verifying

GI Innovation administered the first dose in a global trial combining GI-102 with pasritamig.
The first patient received treatment Monday in the Phase 1b/2 JET trial.
The study evaluates the combination in metastatic castration-resistant prostate cancer patients.